What is Latch Bio?
Latch Bio, headquartered in San Francisco, is at the forefront of building and disseminating the data infrastructure critical for the biocomputing revolution. The company's cloud-based platform offers scientists no-code bioinformatics solutions, enabling them to efficiently store, transform, and visualize their complex biological data. Accessible via any web browser, Latch Bio's tools provide the global scientific community with rapid access to popular bioinformatics pipelines and advanced data visualization capabilities, accelerating research and discovery.
How much funding has Latch Bio raised?
Latch Bio has raised a total of $33M across 2 funding rounds:
Angel/Seed
$5M
Series A
$28M
Angel/Seed (2021): $5M with participation from Lux Capital, General Catalyst, and Haystack
Series A (2022): $28M led by Caffeinated Capital, Coatue, Lux Capital, Hummingbird Ventures, Haystack, and Fifty Years
Key Investors in Latch Bio
Lux Capital
Lux Capital is a New York-based venture capital firm specializing in early-stage and growth-stage companies at the intersection of science and technology. They back founders in frontier areas such as AI, robotics, space, defense, biotechnology, and advanced materials.
General Catalyst
General Catalyst is a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors and stages, backing entrepreneurs with ambitious visions to reshape industries.
Caffeinated Capital
Caffeinated Capital is a thesis and stage agnostic firm that partners with founders from inception through the company's lifecycle, investing across various sectors including life sciences and healthcare.
What's next for Latch Bio?
With a major enterprise-level funding context and a recent strategic investment, Latch Bio is poised for significant expansion and market penetration. The substantial capital infusion will likely fuel further development of its no-code bioinformatics platform, enhance its cloud infrastructure, and broaden its reach within the scientific community. This strategic backing suggests a focus on scaling operations, forging key partnerships, and solidifying its position as a leader in biocomputing data infrastructure. The company's trajectory indicates a strong emphasis on innovation and market adoption, aiming to become an indispensable tool for researchers worldwide.
See full Latch Bio company page
